12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Sigma-Tau, Soligenix sales and marketing update

Soligenix announced on Dec. 27, 2012, that Sigma-Tau returned North American and European commercialization rights to beclomethasone dipropionate (BDP). Sigma-Tau remains eligible for up to $6 million in regulatory and commercialization milestone payments, plus 3% royalties on sales in North America and Europe, as well as 15% of all upfront payments, milestones and other...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >